Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P000013/S027

Trident Alumina Insert (625-0T-XXX); Osteonics ABC/Trident System

HOWMEDICA OSTEONICS CORP · Decision date Sep 17, 2025

FDA DECISIONP000013/S027

What did the FDA decide?

FDA records P000013/S027 as a supplement to PMA P000013, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 17, 2025.

FDA approval order statement

the use of alternative sources for some of the ingredients which are part of the composition of the adhesive coating, TPT-0260, in the Tyvek packaging for the Osteonics ABC/Trident System / Trident Alumina Insert
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Sep 17, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P000013/S027
Regulatory pathway
PMA supplement
Product code
MRA
Decision code
OK30
Decision date
Sep 17, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, hip, semi-constrained, metal/ceramic/ceramic/metal, cemented or uncemented.

Product code
MRA
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P000013/S027 received

    Application receipt date recorded by FDA.

  2. P000013/S027 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P000013. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code MRA

Product / regulatory recordCompanyPathwayDecision dateSource
Depuy Orthopaedics, Inc.PMA supplementSep 4, 2026FDA
Depuy Orthopaedics, Inc.PMA supplementAug 27, 2026FDA
Depuy Orthopaedics, Inc.PMA supplementJul 24, 2026FDA
Depuy Orthopaedics, Inc.PMA supplementJun 3, 2026FDA
Depuy Orthopaedics, Inc.PMA supplementApr 29, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

HOWMEDICA OSTEONICS CORP

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
325 Corporate Dr., Mahwah, NJ, 07430

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records